Upcoming Meetings in the Series:

3rd Next-Generation Conjugates Summit
February 2024
Boston, MA
14th World ADC London
March 2024
London, UK
ADC Analytical Development Summit
April 2024
Boston, MA

The Only Meeting Focusing Solely on ADC Targets

Transforming ADC Target Selection by Identifying Novel & Repurposing Clinically Validated Targets to Develop First & Best-in-Class ADCs

Get the First Step of Your ADC Development Right & Explore the Current Target Landscape at the 3rd ADC Target Selection Summit

Optimizing Your Target, Antibody & Linker-Payload

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2024 event, please get in touch at adc@hansonwade.com

With the number of new clinical ADC targets reaching an all-time high, the 3rd ADC Target Selection Summit returned as the only meeting spotlighting the latest developments in target identification, selection and target specific ADC development that will continue progressing first- and best-in-class ADCs into and through the clinic.

Providing a greater focus on identifying and validating novel targets such as SEZ6, re-examining what makes a good target, and analyzing how novel linker-payload technologies such as topoisomerase I payloads are changing the target selection paradigm; this summit was your unique opportunity to delve into the use of proteomics to ensure you get the first step of drug development right.

This summit joined together 100+ of your peers from Iksuda TherapeuticsMerck &CoAngiexZiel Bio, and Seagen; working in discovery, biology, target identification and validation. With three days of content carefully created to provide you with renewed strategic and scientific insights to progress your ADC pipelines for 2024 and beyond, this was a conversation not to miss.

‘Content was just excellent!’


The 2023 World-Class Speaker Faculty Included:

Bill Mallet

Senior Director

Bolt Biotherapeutics

Dowdy Jackson

Executive Director

Innovent Biologics, Inc.

Elaine Hurt

Executive Director


Manoj Charati

Principal Scientist

Merck & Co.

Natalie Grinshtein

Director - Cancer Target Discovery


‘Opportunities to network were fantastic’

Merck & Co

2023 Partners

Applied Biomath
Untitled design (14)
Untitled design (15)
Website Logo Resize (3)

About the World ADC Series:

The World ADC team ploughs its collective energy in to sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distil this into accessible formats of information exchange – for you. From globally leading conferences to webinars and industry reports, whatever the information you need, World ADC can offer you the insights you need to accelerate your ADC programs.

The value World ADC provides you is the power of insight and connections. Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavours more informed and more robust.

We share a common belief with the industry – that the potential of antibody drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.

Join us at the heart of the ADC community to improve your programmes and be part of the mission to develop better antibody drug conjugate drugs.